ABC | Volume 112, Nº1, January 2019

Original Article Barros et al Regional wall motion and cardiotoxicity prediction Arq Bras Cardiol. 2019; 112(1):50-56 This is an open-access article distributed under the terms of the Creative Commons Attribution License 13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. 14. Nagueh SF, SmisethOA, Appleton CP, Byrd BF 3rd, DokainishH, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277- 314 15. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911- 39. 16. Singal P, Deally C,Weinberg L. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol. 1987;19(8):817-28. 17. De Beer E, Bottone A, Voest E. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol. 2001;415(1):1-11. 18. Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, et al. Anthracyclines induceearlychanges in leftventricularsystolicanddiastolic function:Asingle centre study. PLoS ONE. 2017;12(4):e0175544. 19. NegishiK,NegishiT,HareJL,HaluskaBA,PlanaJC,MarwickTH.Independent and incremental value of deformation indices for prediction of trastuzumab- induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493–8. 20. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603. 21. Thavendiranathan P, Poulin F, Lim K, Plana J, Woo A, Marwick T. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. J Am Coll Cardiol. 2014;63 (25 Pt A):2751-68. 22. Emren SV, Tuluce SY, Levent F, Tuluce K, Kalkan T, Alacacioğlu A, et al. Evaluation of Trastuzumab-induced early cardiac dysfunction using two dimensional Strain Echocardiography. Med Ultrason. 2015;17(4):496‑502. 23. Fei HW, Ali MT, Tan TC, Cheng KH, Salama L, Hua L, et al. Left ventricular global longitudinal strain in HER-2 + breast cancer patients treated with anthracyclines and trastuzumab who develop cardiotoxicity is associated with subsequent recovery of left ventricular ejection fraction. Echocardiography. 2016;33(4):519–26. 24. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987;9(1):184-8. 25. MarchandiseB,SchroederE,BoslyA,DoyenC,WeynantsP,KremerR,etal.Early detectionofdoxorubicincardiotoxicity:InterestofDopplerechocardiographic analysis of left ventricular filling dynamics. AmHeart J. 1989;118(1):92-8. 26. Lange SA, Ebner B, Wess A, Kogel M, Gajda M, Hitschold T, et al. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clin Res Cardiol. 2012;101(6):415-26. 27. Cao L, Cai G, Chang C, Miao AY, Yu XL, Yang ZZ, et al. Diastolic dysfunction occurs early in her2-positive breast cancer patients treated concurrently with radiation therapy and trastuzumab. Oncologist. 2015;20(6):605-14. 28. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo- Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab- mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011;130(3):845-54. 29. Serrano JM, Gonzalez I, Del Castillo S, Muniz J, Morales LJ, Moreno F, et al. Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. Oncologist. 2015;20(8): 864–72. 30. Reuvekamp EJ, Bulten BF, Nieuwenhuis AA, Meekes MRA, de Haan AFJ, Tol J, et al. Does diastolic dysfunction precede systolic dysfunction in trastuzumab- induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). J Nucl Cardiol. 2016;23(4):824-32. 56